Perez-Garcia Georgina, Meneses Alfredo
Departamento de Farmacobiología, CINVESTAV-IPN, México, Mexico.
Behav Brain Res. 2009 Aug 24;202(1):102-13. doi: 10.1016/j.bbr.2009.03.027. Epub 2009 Mar 28.
In an attempt to clarify conflicting results about serotonin (5-hydroxytryptamine, 5-HT) 5-HT(1A) and 5-HT(7) receptors in memory formation, their mRNA expression was determined by RT-PCR in key brain areas for explicit and implicit memory. The time-course (0-120 h) of autoshaped responses was progressive and mRNA 5-HT(1A) or 5-HT(7) receptors expression monotonically augmented or declined in prefrontal cortex, hippocampus and raphe nuclei, respectively. At 24-48 h acutely 8-OH-DPAT (0.062 mg/kg) administration enhanced memory and attenuated mRNA 5-HT(1A)<5-HT(7) receptors expression respect to saline group. WAY100635 (0.3 mg/kg) or SB-269970 (10.0 mg/kg) did not affect the former, partially blocked or reversed the latter, respectively. Furthermore, lower WAY100635 (0.001-0.1 mg/kg) or SB-269970 (1.0-5.0 mg/kg) doses plus 8-OHDPAT not affected memory; however both combinations suppressed or up-regulated mRNA expression 5-HT(1A) or 5-HT(7) receptors. In contrast, AS19 (5.0 mg/kg) facilitated memory consolidation, decreased or increased hippocampal 5-HT(7) and 5-HT(1A) receptors expression. Together these data revealed that, when both 5-HT(1A) and 5-HT(7) receptors were stimulated by 8-OHDPAT under memory consolidation, subtle changes emerged, not evident at behavioral level though detectable at genes expression. Notably, high levels of efficient memory were maintained even when serotonergic tone, via either 5-HT(1A) or 5-HT(7) receptor, was down- or up-regulated. Nevertheless, WAY100635 plus SB-269970 impaired memory consolidation and suppressed their expression. Considering that serotonergic changes are prominent in AD patients with an earlier onset of disease the present approach might be useful in the identification of functional changes associated to memory formation, memory deficits and reversing or even preventing these deficits.
为了澄清关于血清素(5-羟色胺,5-HT)5-HT(1A)和5-HT(7)受体在记忆形成中相互矛盾的结果,通过逆转录聚合酶链反应(RT-PCR)测定了在陈述性和非陈述性记忆的关键脑区中它们的mRNA表达。自动形成反应的时间进程(0-120小时)是渐进的,前额叶皮层、海马体和中缝核中5-HT(1A)或5-HT(7)受体的mRNA表达分别单调增加或下降。在24-48小时时,急性给予8-羟基二丙胺(8-OH-DPAT,0.062mg/kg)可增强记忆,并使5-HT(1A)<5-HT(7)受体的mRNA表达相对于生理盐水组减弱。WAY100635(0.3mg/kg)或SB-269970(10.0mg/kg)对前者无影响,分别部分阻断或逆转后者。此外较低剂量的WAY100635(0.001-0.1mg/kg)或SB-269970(1.0-5.0mg/kg)加8-OHDPAT不影响记忆;然而,两种组合均抑制或上调5-HT(1A)或5-HT(7)受体的mRNA表达。相比之下,AS19(5.0mg/kg)促进记忆巩固,降低或增加海马体中5-HT(7)和5-HT(1A)受体的表达。这些数据共同表明,在记忆巩固过程中,当5-HT(1A)和5-HT(7)受体均受到8-OHDPAT刺激时,会出现细微变化,虽然在行为水平上不明显,但在基因表达水平上可检测到。值得注意的是,即使通过5-HT(1A)或5-HT(7)受体下调或上调血清素能张力,高效记忆的高水平仍得以维持。然而,WAY100635加SB-269970会损害记忆巩固并抑制它们的表达。鉴于血清素能变化在疾病发病较早的阿尔茨海默病(AD)患者中很突出,目前的方法可能有助于识别与记忆形成、记忆缺陷相关的功能变化,并逆转甚至预防这些缺陷。